Literature DB >> 19106604

NALP3 inflammasome functional polymorphisms and gout susceptibility.

Zhi-Min Miao1, Shi-Hua Zhao, Sheng-Li Yan, Chang-Gui Li, Yan-Gang Wang, Dong-Mei Meng, Li Zhou, Qing-Sheng Mi.   

Abstract

Gout is the most common autoinflammatory arthritis characterized by elevated serum urate and recurrent attacks of intra-articular crystal deposition of monosodium urate (MSU). Although the pathogenesis of gout is still unclear, accumulated studies indicate that genetic factors trigger gout development, including some susceptibility genes that control the production and clearance of urate and lead to hyperuricemia. However, the epidemiological evidence suggests that only less than 10% of hyperuricemia patients develop gout, indicating that other genes unrelated to the urate metabolism may also contribute to the diseases susceptibility. Accumulated evidences have implied that MSU crystal-induced inflammation is a paradigm of innate immunity and that NALP3 inflammasome, an innate immune complex containing NALP3, ASC and CARD-8, is involved in gout development. Recent studies suggest that NALP3 and CARD-8 functional mutations contribute to the development of autoinflammatory diseases including hereditary periodic fever syndrome, arthritis as well as hypertension susceptibility. Taking into account these genetic findings, here we would like to propose a novel hypothesis that functional mutations in NALP3 inflammasome may make NALP3 inflammasome as attractive susceptibility candidates and genetic markers for gout. Further clinical genetic studies need to be performed to confirm the role of NALP3 inflammasome in the etiology of gout.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19106604     DOI: 10.4161/cc.8.1.7325

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  8 in total

1.  rs3806268 of NLRP3 gene polymorphism is associated with the development of primary gout.

Authors:  Jianping Deng; Wen Lin; Yunpeng Chen; Xin Wang; Zhong Yin; Chunhong Yao; Tangbing Liu; Yonghong Lv
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  Association analysis between genetic variants in interleukin genes among different populations with hyperuricemia in Xinjiang Autonomous Region.

Authors:  Bei Zhang; Yuping Sun; Yuanyuan Li; Jiahui Yu; Tingting Wang; He Xia; Changgui Li; Shiguo Liu; Hua Yao
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

3.  Characteristics of ocular abnormalities in gout patients.

Authors:  Jing Lin; Gui-Qiu Zhao; Cheng-Ye Che; Shan-Shan Yang; Qian Wang; Chang-Gui Li
Journal:  Int J Ophthalmol       Date:  2013-06-18       Impact factor: 1.779

4.  Acute oral toxicity assessment and anti-hyperuricemic activity of Alocasia longiloba extracts on Sprague-Dawley rats.

Authors:  Ferid Abdulhafiz; Mohd Farhan Hanif Reduan; Zulhazman Hamzah; Zulhisyam Abdul Kari; Mahmoud A O Dawood; Arifullah Mohammed
Journal:  Saudi J Biol Sci       Date:  2022-01-29       Impact factor: 4.052

Review 5.  The genetics revolution in rheumatology: large scale genomic arrays and genetic mapping.

Authors:  Stephen Eyre; Gisela Orozco; Jane Worthington
Journal:  Nat Rev Rheumatol       Date:  2017-06-01       Impact factor: 20.543

Review 6.  Application of nanotechnologies for improved immune response against infectious diseases in the developing world.

Authors:  Michael Look; Arunima Bandyopadhyay; Jeremy S Blum; Tarek M Fahmy
Journal:  Adv Drug Deliv Rev       Date:  2009-11-14       Impact factor: 15.470

7.  The role of the NLRP3 inflammasome in gout.

Authors:  Sarah R Kingsbury; Philip G Conaghan; Michael F McDermott
Journal:  J Inflamm Res       Date:  2011-03-13

8.  Chrysophanol inhibits NALP3 inflammasome activation and ameliorates cerebral ischemia/reperfusion in mice.

Authors:  Nan Zhang; Xiangjian Zhang; Xiaoxia Liu; Hong Wang; Jing Xue; Jingying Yu; Ning Kang; Xiaolu Wang
Journal:  Mediators Inflamm       Date:  2014-04-29       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.